Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

This article was originally published here

The study has showed a significantly higher proportion of patients with resistant hypertension (RHTN) and CKD taking Veltassa remained on spironolactone therapy compared against patients taking placebo at

The post Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply